Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Liabilities and Shareholders Equity (2016 - 2025)

iBio (IBIO) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $64.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 196.78% to $64.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $170.8 million, a 36.56% increase, with the full-year FY2025 number at $23.2 million, down 19.31% from a year prior.
  • Liabilities and Shareholders Equity was $64.4 million for Q4 2025 at iBio, roughly flat from $64.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $147.0 million in Q2 2021 to a low of $19.1 million in Q1 2025.
  • A 5-year average of $68.2 million and a median of $51.0 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 237.98% in 2021, then tumbled 61.91% in 2025.
  • iBio's Liabilities and Shareholders Equity stood at $126.4 million in 2021, then tumbled by 59.03% to $51.8 million in 2022, then tumbled by 34.32% to $34.0 million in 2023, then tumbled by 36.23% to $21.7 million in 2024, then skyrocketed by 196.78% to $64.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Liabilities and Shareholders Equity are $64.4 million (Q4 2025), $64.2 million (Q3 2025), and $23.2 million (Q2 2025).